Does Medicare Supplemental Insurance Protect Beneficiaries With Cancer?

Published Jan 30, 2014
Baltimore, MD, USA – In the United States, cancer is more prevalent in the elderly population, with more than 1.5 million new cases expected each year. It is the second leading cause of death in the US after heart disease, and is associated with high treatment costs. Unfortunately, Medicare does not cover all of these costs.  Regardless of the level of generosity of their supplemental insurance plans, Medicare beneficiaries newly diagnosed with cancer must still try to finance their cancer treatment, possibly liquidating assets or borrowing from family members. Using Medicare administrative data, researchers from the University of Maryland School of Pharmacy and the University of Vermont College of Medicine compared the total health care spending of Medicare beneficiaries newly diagnosed with cancer to the general Medicare population without cancer to examine the effect of having supplemental insurance coverage such as Medigap. The researchers discovered that, over a time period of two years, expenditures for Medicare beneficiaries with cancer was $15,605 more than the general Medicare population (after taking into account differences in demographics, socio-economic and health status). Despite the presence of different types of supplemental coverage, total expenditures did not widely vary and were essentially flat across the types of supplemental insurance studied. Mujde Z. Erten, PhD, Assistant Professor in the Department of Surgery at the University of Vermont College of Medicine, and the lead author of the study says, “Our results suggest that beneficiaries with cancer would be unlikely to reduce their total spending substantially in response to restrictions on access to Medicare supplemental coverage, and could end up with a much greater burden in out-of-pocket spending.”  The full study, “The Effect of Supplemental Medical and Prescription Drug Coverage on Health Care Spending for Medicare Beneficiaries with Cancer,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Advancing the Economics of Mental Health: A Global Perspective

Mar 12, 2025

Value in Health, the official journal of ISPOR announced the publication of a special themed section of research papers exploring mental health economics, highlighting impacts on caregivers, productivity, and interventions’ cost-effectiveness.

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×